Drug Target Review rounds up some of the latest developments in materials developed for medical applications, including hydrogels, implants and more.
List view / Grid view
Hannah Balfour (European Pharmaceutical Review)
Filter the results
The US Food and Drug Administration (FDA) issued the letter after finding the products contain chlorine dioxide, a powerful bleaching agent with potentially fatal side effects.
Experiments testing the artificial cardiac patch in pigs and rats showed the patch can reduce scarring and improve cardiac function after a heart attack.
The European Medicines Agency (EMA) and other authorities have created a new shortage reporting system and are looking into how regulations can be applied more flexibly during the COVID-19 pandemic.
A report states that three quarters of the roughly 230 nanopharmaceuticals in clinical development are for use as targeted cancer therapeutics.
Researchers found that the combination of lopinavir-ritonavir HIV antivirals led to rapid symptom improvement in COVID-19 patients.
In the face of the coronavirus pandemic, restrictions and extreme situations may require changes to ongoing or upcoming clinical trials. These are the key recommendations from the EC, MHRA and FDA.
A pilot trial of convalescent plasma therapy in 10 severe COVID-19 patients has shown it may be a safe and promising therapeutic option.
The European Medicines Agency has released recommendations about which patients could benefit from remdesivir and the possible criteria for compassionate use of the drug.
The coalition has been formed to find R&D solutions for low- and middle-income countries to limit the impact of the COVID-19 pandemic in areas with fragile healthcare systems.
Pharmaceutical manufacturing can lead to the contamination of water ways and supply. Here, the ultimate effects from pharma’s role in environmental pollution is examined.
The institute has paused cancer research and repurposed its laboratories and scientists to provide a rapid COVID-19 testing facility for NHS staff and other key workers.
The developers of Avigan have increased production and announced a Phase III clinical trial testing its efficacy against COVID-19.
Cenobamate’s application was based on a global clinical trials programme enrolling over 1,900 adults with uncontrolled focal-onset seizures.
The bill includes $80 million funding for the US FDA to continue their COVID-19 response efforts and extra powers to modernise over-the-counter drug regulation.